A Canadian Perspective by Dr. Michael Ong on the KEYNOTE-045 and KEYNOTE-052 trials that assessed the efficacy and safety of pembrolizumab in patients with urothelial carcinoma

The therapeutic landscape of metastatic urothelial carcinoma (mUC) is rapidly changing with the introduction of immune checkpoint inhibitors (ICIs). Nevertheless, mUC remains a challenging cancer to treat, and the selection of a suitable therapy is dependent on...